Company intelligence / Profile preview

Neuphoria Therapeutics Inc.

Burlington, Massachusetts, United Statesneuphoriatx.com ↗

Ownership: Public · NEUP
Employees: ~24
Development stage: Phase 2

Overview

Lead candidate BNC210 is in Phase 3 for social anxiety disorder and Phase 2b for PTSD. BNC101 has completed Phase 1 for cancer stem cells. BNC105 is in Phase 2 for refractory colorectal cancer and Phase 1 for chronic lymphocytic leukemia.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

7 assets

soclenicant

6 more assets in the full pipeline.

Request access →

Partnerships

Merck & Co., Inc.Carina Biotech

Financials

Market cap: $20.2M
Total revenue: $0
Enterprise value: $752.5K

Beyond the preview

Go deeper on Neuphoria Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuphoria Therapeutics Inc..

Explore the full profile